title: [Ibuprofen versus indomethacin in the preterm persistent patent ductus arteriosus therapy: review and meta-analysis].
abstract: BACKGROUND
  Persistent patent ductus arteriosus (PDA) is a common pathology in the preterm whose traditional treatment has been indomethacin. Recently, ibuprofen has shown its effectiveness in closing the PDA with less hemodynamic effects. The objective of this paper is to review the current literature in order to determine if there is any benefit of ibuprofen versus indomethacin in the PDA therapy.
  
  
  METHODS
  Eleven trials comparing intravenous ibuprofen versus indomethacin in the treatment of PDA confirmed by echocardiography in < 35 weeks preterm or < 1,500 g birth weight were included. A meta-analysis of the trials data was performed.
  
  
  RESULTS
  No trial show statistically significant differences in the failure of closing PDA, neither the meta-analysis (RR 0.96 [CI 95 %: 0.74-1.26], with a power of 0.995). No differences were found in the rate of reopening and surgical ligation. Complications were similar, except for a significant lower incidence of oliguria in the ibuprofen group (RR 0.23 [CI 95 %: 0.10-0.51]). There were no differences in the respiratory outcomes (RR of bronchopulmonary dysplasia (BPD) at 28 days 1.32 [CI 95 %: 0.99-1.76]).
  
  
  CONCLUSIONS
  In our revision ibuprofen was as effective as indomethacin in closing PDA. No significant differences were found in the incidence of complications except for less renal impairment with ibuprofen. A higher risk of BPD in the ibuprofen group is not confirmed, although more studies are needed.
authors.affiliation: Servicio de Neonatología, Hospital Universitario Infantil La Fe, Valencia, España. annagim@terra.es
authors.forename: A
authors.initials: A
authors.lastname: Gimeno Navarro
authors.forename: V
authors.initials: V
authors.lastname: Modesto Alapont
authors.forename: F
authors.initials: F
authors.lastname: Morcillo Sopena
authors.forename: C
authors.initials: C
authors.lastname: Fernández Gilino
authors.forename: I
authors.initials: I
authors.lastname: Izquierdo Macián
authors.forename: A
authors.initials: A
authors.lastname: Gutiérrez Laso
mesh_terms: D018712:Analgesics, Non-Narcotic / Q000627:therapeutic use*; D000894:Anti-Inflammatory Agents, Non-Steroidal / Q000627:therapeutic use*; D004374:Ductus Arteriosus, Patent / Q000175:diagnosis / Q000188:drug therapy*; D004452:Echocardiography; D006801:Humans; D007052:Ibuprofen / Q000627:therapeutic use*; D007213:Indomethacin / Q000627:therapeutic use*; D007231:Infant, Newborn; D007232:Infant, Newborn, Diseases; D007234:Infant, Premature
chemical_list: D018712:Analgesics, Non-Narcotic; D000894:Anti-Inflammatory Agents, Non-Steroidal; D007052:Ibuprofen; D007213:Indomethacin